Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)
July 22 2021 - 8:00AM
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the
Securities Market Act (BlackRock, Inc.)
ORION CORPORATION STOCK EXCHANGE RELEASE / MAJOR SHAREHOLDER
ANNOUNCEMENTS22 JULY 2021 at 3:00 EEST
Orion Corporation: Disclosure Under Chapter 9 Section 10
of the Securities Market Act
(BlackRock,
Inc.)
Orion Corporation has received a disclosure under Chapter 9,
Section 5 of the Securities Market Act, according to which the
total number of Orion shares owned directly or indirectly by
BlackRock, Inc. and its funds increased on 21 July 2021 above five
(5) per cent of Orion Corporation’s total shares.
Total positions of BlackRock, Inc. and its funds subject to
notification:
|
|
% of shares and voting rights (total
of point A) |
% of shares and voting rights through financial
instruments (total of
point B) |
Total of both in % (points
A + B) |
Total number of shares and voting rights of
issuer |
|
Resulting situation on the date on which threshold was crossed or
reached |
5.08% shares Below 5% voting rights |
0.04% shares Below 5% voting rights |
5.13% shares Below 5% voting rights |
141,134,278 shares 806,258,215 voting rights |
|
Position of previous notification (if applicable) |
4.99% shares Below 5% voting rights |
0.04% shares Below 5% voting rights |
5.03% shares Below 5% voting rights |
|
Notified details of the resulting situation on the date on which
the threshold was crossed:
Point A: Shares and voting rights:
|
Class/type of sharesISIN code |
Number of shares and voting rights |
% of shares and voting rights |
|
|
Direct (SMA 9:5) |
Indirect (SMA 9:6 and 9:7) |
Direct (SMA 9:5) |
Indirect (SMA 9:6 and 9:7) |
|
FI0009014377 |
|
7,181,075 shares Below 5% voting rights |
|
5.08% shares Below 5% voting rights |
|
POINT A SUBTOTAL |
7,181,075 shares Below 5% voting rights |
5.08% shares Below 5% voting rights |
Point B: Financial instruments according to SMA 9:6a:
|
Type of
financial instrument |
Expiration date |
Exercise / Conversion
Period |
Physical or cash
settlement |
Number of shares and voting rights |
% of shares and voting rights |
|
Securities Lent |
N/A |
N/A |
Physical |
46,754 sharesBelow 5% voting rights |
0.03% sharesBelow 5% voting rights |
|
CFD |
N/A |
N/A |
Cash |
12,717 shares Below 5% voting rights |
0.00% sharesBelow 5% voting rights |
|
|
|
|
POINT B
SUBTOTAL |
59,471 shares Below 5% voting rights |
0.04% shares Below 5% voting rights |
Orion Corporation
| Timo
LappalainenPresident and CEO |
|
Olli HuotariSVP,
Corporate Functions |
|
Contact
person:Terhi Ormio, VP, Communications, Orion
Corporationtel. +358 10 426 4646
Publisher:Orion
CorporationCommunicationsOrionintie 1A, FI-02200 Espoo,
Finlandhttp://www.orion.fi/enhttp://www.twitter.com/OrionCorpIR
Orion is a globally operating Finnish pharmaceutical company – a
builder of well-being. Orion develops, manufactures and markets
human and veterinary pharmaceuticals and active pharmaceutical
ingredients. The company is continuously developing new drugs and
treatment methods. The core therapy areas of Orion's pharmaceutical
R&D are neurological disorders, oncology and respiratory
diseases for which Orion develops inhaled pulmonary medication.
Orion's net sales in 2020 amounted to EUR 1,078 million and the
company had about 3,300 employees at the end of the year. Orion's A
and B shares are listed on Nasdaq Helsinki.